Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy
BackgroundThe renin-angiotensin-aldosterone system (RAAS) members, especially Ang II and aldosterone, play key roles in the pathogenesis of diabetic cardiomyopathy (DCM). Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers combined with aldosterone receptor antagonists (mineral...
Saved in:
Main Authors: | Lin Xie (Author), Dejin Zang (Author), Jianmin Yang (Author), Fei Xue (Author), Wenhai Sui (Author), Yun Zhang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fibrosis and dysfunction via regulating ACE2 shedding and myofibroblast transformation
by: Jing Cheng, et al.
Published: (2022) -
New Clinical Aspects of Eplerenone Use in Clinical Practice
by: S. R. Gilyarevskiy, et al.
Published: (2018) -
ADAM17-Mediated Shedding of Inflammatory Cytokines in Hypertension
by: Thyago M. de Queiroz, et al.
Published: (2020) -
Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability
by: Muhammad Ayub Khan, et al.
Published: (2021) -
A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015)